Cancer Biology & Genetics Program
The Scott Lowe Lab
Research
About the Scott Lowe Lab
Our laboratory studies tumor-suppressor networks controlling apoptosis and senescence and how their disruption influences malignant behavior.
Research Projects
Featured News
Publications
A gene–environment-induced epigenetic program initiates tumorigenesis. Alonso-Curbelo, D, Ho, YJ, Burdziak, C, Maag, JLV, Morris IV, JP, Chandwani, R, Chen, HA, Tsanov, KM, Barriga, FM, Luan, W, Tasdemir, N, Livshits, G, Azizi, E, Chun, J, Wilkinson, JE, Mazutis, L, Leach, SD, Koche, R, Pe’er, D, Lowe, SW. Nature. 2021 Feb;590(7847):642-648. PMID: 33536616.
Senolytic CAR T Cells Reverse Senescence-Associated Pathologies. Amor, C, Feucht, J, Leibold, J, Ho, YJ, Zhu, C, Alonso-Curbelo, D, Mansilla-Soto, J, Boyer, JA, Li, X, Giavridis, T, Kulick, A, Houlihan, S, Peerschke, E, Friedman, SL, Ponomarev, V, Piersigilli, A, Sadelain, M, Lowe, SW. Nature. 2020 Jul;583(7814):127-132. PMID: 32555459.
Senescence-Induced Vascular Remodeling Creates Therapeutic Vulnerabilities in Pancreas Cancer. Ruscetti, M, Morris IV, JP, Mezzadra, R, Russell, J, Leibold, J, Romesser, PB, Simon, J, Kulick, A, Ho, YJ, Fennell, M, Li, J, Norgard, RJ, Wilkinson, JE, Alonso-Curbelo, D, Sridharan, R, Heller, DA, de Stanchina, E, Stanger, BZ, Sherr, CJ, Lowe, SW. Cell. 2020 Apr 16;181(2):424-441.e21. PMID: 32234521.
α-Ketoglutarate links p53 to cell fate during tumor suppression. Morris IV, JP, Yashinskie, JJ, Koche, R, Chandwani, R, Tian, S, Chen, C-C, Baslan, T, Marinkovic, ZS, Sanchez-Rivera, FJ, Leach, SD, Carmona-Fontaine, C, Thompson, CB, Finley, LWS, Lowe, SW. Nature. 2019 Sep;573(7775):595-599. PMID: 31534224.
NK cell-mediated cytotoxicity contributes to tumor control by a cytostatic drug combination. Ruscetti, M, Leibold, J, Bott, MJ, Fennell, M, Kulick, A, Chen, C-C, Baslan, T, Salgado, NR, Sanchez-Rivera, FJ, Tian, S, Romesser PB, Poirier, JT, Rudin, CM, de Stanchina, E, Manchado, E, Sherr, CJ, and Lowe, SW. Science. 2018 Dec 21;362(6421):1416-1422. PMID: 30573629.
People
Scott W. Lowe, PhD
Chair, Cancer Biology & Genetics Program, SKI; Chair, Geoffrey Beene Cancer Research Center; Investigator, Howard Hughes Medical Institute
- Cancer biologist Scott Lowe uses genetically engineered mouse models to study how the genetic alterations in cancer cells contribute to tumorigenesis, alter treatment response, and create molecular vulnerabilities that may be targeted therapeutically.
- PhD, Massachusetts Institute of Technology
- lowes@mskcc.org
- Email Address
- 646-888-3342
- Office Phone
- Download CV
- PDF File
Members
- PhD, Universitat Pompeu Fabra and Institute for Research in Biomedicine [IRB] Barcelona (Spain)
- 646-888-3340
- Lab Phone
- PhD, University of Glasgow, Scotland, United Kingdom
- 646-888-3340
- Lab Phone
- BS, University of California, Santa Barbara, CA
- 646-888-3340
- Lab Phone
- PhD, Stanford University, Stanford, CA
- 646-888-3340
- Lab Phone
- PhD, Autonomous University of Madrid, Spain
- 646-888-3340
- Lab Phone
- MD, Johannes-Gutenberg-University, School of Medicine, Mainz, Germany
- 646-888-3340
- Lab Phone
- PhD, Cold Spring Harbor Laboratory, New York
- 646-888-3340
- Lab Phone
- BS, The College of New Jersey, Ewing, NJ
- 646-888-3340
- Lab Phone
- PhD, Netherlands Cancer Institute (Netherlands)
- 646-888-3340
- Lab Phone
- PhD, Weill Cornell Medical College, New York, NY
- 646-888-3340
- Lab Phone
- MS, German Cancer Research Center (DKFZ), Heidelberg (Germany)
- 646-888-3340
- Lab Phone
- PhD, Harvard University, Cambridge, MA
- 646-888-3340
- Lab Phone
- PhD, Harvard University, Cambridge, MA
- 646-888-3340
- Lab Phone
- PhD, Gerstner Sloan Kettering Graduate School of Biomedical Sciences, New York, NY
- 646-888-3340
- Lab Phone
- PhD, Columbia University, New York, NY
- 646-888-3340
- Lab Phone
- MD, Capital University of Medical Sciences (China)
- 646-888-3340
- Lab Phone
- MSc Oxon, University of Oxford (England)
- 646-888-3340
- Lab Phone
- MS, University of Turku (Finland)
- 646-888-3340
- Lab Phone
- MS, Stony Brook University
- PhD, Centro Nacional de Investigaciones Oncológicas [CNIO] (Spain)
- MD, Westphalian Wilhelms University (Germany)
- MD, Universidad Complutense de Madrid (Spain)
- PhD, Gerstner Sloan Kettering Graduate School of Biomedical Sciences, New York, NY
- PhD, Medical Research Council, Clinical Sciences Centre, Imperial College London (UK)
- PhD, University of Konstanz (Germany)
- PhD, Weill Cornell Medical College, New York, NY
- MD, National Taiwan University (Taiwan)
- BS, National Taiwan University (Taiwan)
- PhD, Gerstner Sloan Kettering Graduate School of Biomedical Sciences, New York, NY
- PhD, University of Michigan, Ann Arbor, MI
- PhD, University of Melbourne (Australia)
- PhD, Watson School of Biological Sciences, Cold Spring Harbor Laboratory, NY
- PhD, Weill Cornell Medical College, New York, NY
- PhD, Northwestern University Feinberg School of Medicine, Chicago, IL
- MS, The Ohio State University, Columbus, OH
- PhD, Weill Cornell Medical College, New York, NY
- PhD, Weill Cornell Medical College, New York, NY
- PhD, Gerstner Sloan Kettering Graduate School, New York, NY
- PhD, University of Heidelberg (Germany)
- MD, University of Tübingen (Germany)
- PhD, Albert Einstein College of Medicine, New York, NY
- PhD, The Rockefeller University, New York, NY
- PhD, Massachusetts Institute of Technology, Cambridge, MA
- PhD, Weill Cornell Medical College, New York, NY
- PhD, Centro Nacional de Investigaciones Oncológicas [CNIO] (Spain)
- PhD, Centro Nacional de Investigaciones Oncológicas [CNIO] (Spain)
- PhD, Baylor College of Medicine, Houston, TX
- PhD, Watson School of Biological Sciences, Cold Spring Harbor Laboratory, NY
- PhD, University of Frankfurt (Germany)
- PhD, University of California, San Francisco, CA
- MD-PhD, Weill Cornell Medical College, New York, NY
- PhD, The Scripps Research Institute, La Jolla, CA
- PhD, University of California, Los Angeles, CA
- MD, Hannover Medical School (Germany)
- MD, University of Leipzig (Germany)
- PhD, Watson School of Biological Sciences, Cold Spring Harbor Laboratory, NY
- MD, RWTH Aachen (Germany)
- PhD, Watson School of Biological Sciences, Cold Spring Harbor Laboratory, NY
- MD, Medical University of China (China)
- PhD, Stony Brook University, New York
- BS, Carnegie Mellon University, Pittsburgh, PA
- MS, New York University
- BS, University of Connecticut
- AALAS Technician Certification
- BS, Yale University
- BS, Molloy College
- BA, City College of New York
- MS, New York University
- BSE, University of Pennsylvania
- BS, Binghamton University
- BS, Stony Brook University
- BS, Fairleigh Dickinson University
- BA, Hunter College
- BS, University of Cincinnati
Lab Alumni
Lab News & Events
Open Positions
To learn more about available postdoctoral opportunities, please visit our Career Center
Get in Touch
-
Lab Head Email
-
Office Phone
-
Office Fax
-
Lab Phone
Lab Resources
Scott Lowe Lab Plasmid and Animal Requests
Request plasmids through Addgene More »
For plasmids not listed on Addgene, please contact our Lab Manager, Anne Trumble-Koncelik, trumblea@mskcc.org.
For animal requests, please contact our Mouse Colony Manager, Janelle Simon, simonj@mskcc.org.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Scott W. Lowe discloses the following relationships and financial interests:
-
Algen
Intellectual Property Rights -
Blueprint Medicines
Ownership / Equity Interests; Provision of Services -
Constellation Pharmaceuticals
Ownership / Equity Interests; Provision of Services -
Eli Lilly and Company
Provision of Services -
Faeth Therapeutics, Inc
Ownership / Equity Interests; Provision of Services (uncompensated)
-
Geras Bio Inc
Ownership / Equity Interests; Provision of Services (uncompensated) -
Mirimus
Ownership / Equity Interests; Provision of Services -
Oric Pharmaceuticals
Ownership / Equity Interests; Provision of Services -
PMV Pharma
Ownership / Equity Interests; Provision of Services -
Petra Pharma Corporation
Ownership / Equity Interests; Provision of Services
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.